2 completed, 1 terminated. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
Follow tetrathiomolybdate: new trials by email Literature Review of tetrathiomolybdate trials Research Report on tetrathiomolybdate
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease ALXN1840, SoC Therapy - Wilson Disease | Phase 3 | Terminated | Alexion Pharmaceuticals, Inc. | 214 | 2018-02-22 | 2024-06-17 |
| Study Comparing Tetrathiomolybdate vs Standard Treatment in Primary Biliary Cirrhosis Tetrathiomolybdate, Placebo - Primary Biliary Cirrhosis | Phase 3 | Completed | George Brewer | 29 | 2006-04-01 | 2017-05-23 |
| Study of Tetrathiomolybdate in Patients With Wilson Disease tetrathiomolybdate, trientine - Wilson Disease | Phase 3 | Completed | National Center for Research Resources (NCRR) | 90 | 1994-01-01 | 2006-05-09 |
Hepatolenticular Degeneration (2) · Liver Cirrhosis, Biliary (1) · Metabolism, Inborn Errors (1) · Rare Diseases (1)
Alexion Pharmaceuticals, Inc. (1) · George Brewer (1) · National Center for Research Resources (NCRR) (1)
United States (3) · Australia (1) · Austria (1) · Canada (1) · Czechia (1) · Denmark (1) · France (1) · Germany (1) · Hong Kong (1) · Hungary (1) · Israel (1) · Japan (1) · New Zealand (1) · Poland (1) · Russia (1)
Eugene S. Swenson, M.D., Ph.D. (1) · George J. Brewer (1)
2017 (1)